Read the quarter in context.
A source-linked quarter view: reported numbers, management language, guidance, and the risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹2,167 Cr
verified against source
Revenue YoY
16.6%
reported change
EBITDA
₹491 Cr
latest reported figure
Source
screener in
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
Fortis Healthcare delivered a strong Q1 FY26, with consolidated revenue of INR 2,167 crore (+16.6% YoY) and EBITDA of INR 491 crore (+43.2% YoY), driving margin expansion of 420 bps to 22.6%. The hospital business led growth with revenue up 18.6% to INR 1,838 crore, supported by a 10.2% increase in RPOB, improved case mix (oncology +28% YoY, robotic surgeries +75% YoY), and occupancy rising to 69%. Diagnostics revenue grew 7.4% to INR 369 crore, with EBITDA margins surging to 23% from 16.1% YoY. Management guided for 200 bps margin improvement for the full year and expects diagnostics margins to sustain 22-23%. The Gleneagles O&M agreement adds ~700 beds at 3% net revenue fee, providing low-risk EBITDA accretion. Key risks include slower ramp-up of new brownfield beds and potential dilution from integrating underperforming Gleneagles assets.
Colored figures show movement against the previous available record.
Guidance to track
- Management reiterated guidance of 200 bps margin expansion for the hospital business in FY26, supported by case mix improvement and operational efficiencies.
- Management expects diagnostics EBITDA margins to remain in the 22-23% range for the full year, with Q2 typically stronger.
- Fortis plans to add approximately 900 beds in FY26, including the recently acquired Shrimann Superspecialty Hospital, with about half becoming operational in the current fiscal.
- Agilus expects revenue growth to trend in the high single-digits over the next few quarters, moving to early double-digits in 6-8 quarters.
Risks flagged
- Analyst raised concern that Gleneagles facilities have historically low margins (~3-4%), and the 3% fee may not capture full upside from operational improvements.
- New bed additions (e.g., Manesar, FMRI) may take time to reach optimal occupancy, delaying margin contribution.
- Despite margin improvement, diagnostics revenue growth of 7.4% remains modest; management expects only gradual acceleration to double-digits.
Key quotes
- We have witnessed a healthy start to the financial year 2026. Our hospital business continues to perform well, both in terms of revenue and margins.
- These facilities have a good potential. They are located well in the micromarkets they are in. We believe that the full potential of these hospitals has not yet been realized.
- We are sticking to our guidance, which we have provided in the beginning of the year, 2% margin improvement. We are excited with the first quarter number.
Research modules